Overall Survival After Whole-Brain Radiation Therapy for Intracerebral Metastases from Testicular Cancer

Dirk Rades; Liesa Dziggel; Theo Veninga; Amira Bajrovic; Steven E Schild

doi:10.21873/anticanres.11042

Overall Survival After Whole-Brain Radiation Therapy for Intracerebral Metastases from Testicular Cancer

Standard

Overall Survival After Whole-Brain Radiation Therapy for Intracerebral Metastases from Testicular Cancer. / Rades, Dirk; Dziggel, Liesa; Veninga, Theo; Bajrovic, Amira; Schild, Steven E.

In: ANTICANCER RES, Vol. 36, No. 9, 09.2016, p. 4817-9.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rades, D, Dziggel, L, Veninga, T, Bajrovic, A & Schild, SE 2016, 'Overall Survival After Whole-Brain Radiation Therapy for Intracerebral Metastases from Testicular Cancer', ANTICANCER RES, vol. 36, no. 9, pp. 4817-9. https://doi.org/10.21873/anticanres.11042

APA

Rades, D., Dziggel, L., Veninga, T., Bajrovic, A., & Schild, S. E. (2016). Overall Survival After Whole-Brain Radiation Therapy for Intracerebral Metastases from Testicular Cancer. ANTICANCER RES, 36(9), 4817-9. https://doi.org/10.21873/anticanres.11042

Vancouver

Rades D, Dziggel L, Veninga T, Bajrovic A, Schild SE. Overall Survival After Whole-Brain Radiation Therapy for Intracerebral Metastases from Testicular Cancer. ANTICANCER RES. 2016 Sep;36(9):4817-9. https://doi.org/10.21873/anticanres.11042

Bibtex

@article{76a87f204dd54f4c933119d7d435441a,

title = "Overall Survival After Whole-Brain Radiation Therapy for Intracerebral Metastases from Testicular Cancer",

abstract = "BACKGROUND/AIM: To identify predictors and develop a score for overall survival of patients with intracerebral metastasis from testicular cancer.PATIENTS AND METHODS: Whole-brain radiation therapy program, age, Karnofsky performance score (KPS), number of intracerebral metastases, number of other metastatic sites and time between testicular cancer diagnosis and radiation therapy were analyzed for their association with overall survival in eight patients.RESULTS: KPS of 80-90% was significantly associated with better overall survival (p=0.006), one or no other metastatic sites showed a trend for a better outcome (p=0.10). The following scores were assigned: KPS 60-70%=0 points, KPS 80-90%=1 point, ≥2 other metastatic sites=0 points, 0-1 other metastatic sites=1 point. Two groups, with 0 and with 1-2 points, were formed. Overall survival rates were 33% vs. 100% at 6 months and 0% vs. 100% at 12 months (p=0.006), respectively.CONCLUSION: A simple instrument enabling physicians to judge the overall survival of patients with intracerebral metastasis from testicular cancer is provided.",

keywords = "Adult, Aged, Brain, Brain Neoplasms, Humans, Kaplan-Meier Estimate, Karnofsky Performance Status, Male, Middle Aged, Neoplasm Metastasis, Prognosis, Survival Rate, Testicular Neoplasms, Journal Article",

author = "Dirk Rades and Liesa Dziggel and Theo Veninga and Amira Bajrovic and Schild, {Steven E}",

year = "2016",

month = sep,

doi = "10.21873/anticanres.11042",

language = "English",

volume = "36",

pages = "4817--9",

journal = "ANTICANCER RES",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "9",

}

RIS

TY - JOUR

T1 - Overall Survival After Whole-Brain Radiation Therapy for Intracerebral Metastases from Testicular Cancer

AU - Rades, Dirk

AU - Dziggel, Liesa

AU - Veninga, Theo

AU - Bajrovic, Amira

AU - Schild, Steven E

PY - 2016/9

Y1 - 2016/9

N2 - BACKGROUND/AIM: To identify predictors and develop a score for overall survival of patients with intracerebral metastasis from testicular cancer.PATIENTS AND METHODS: Whole-brain radiation therapy program, age, Karnofsky performance score (KPS), number of intracerebral metastases, number of other metastatic sites and time between testicular cancer diagnosis and radiation therapy were analyzed for their association with overall survival in eight patients.RESULTS: KPS of 80-90% was significantly associated with better overall survival (p=0.006), one or no other metastatic sites showed a trend for a better outcome (p=0.10). The following scores were assigned: KPS 60-70%=0 points, KPS 80-90%=1 point, ≥2 other metastatic sites=0 points, 0-1 other metastatic sites=1 point. Two groups, with 0 and with 1-2 points, were formed. Overall survival rates were 33% vs. 100% at 6 months and 0% vs. 100% at 12 months (p=0.006), respectively.CONCLUSION: A simple instrument enabling physicians to judge the overall survival of patients with intracerebral metastasis from testicular cancer is provided.

AB - BACKGROUND/AIM: To identify predictors and develop a score for overall survival of patients with intracerebral metastasis from testicular cancer.PATIENTS AND METHODS: Whole-brain radiation therapy program, age, Karnofsky performance score (KPS), number of intracerebral metastases, number of other metastatic sites and time between testicular cancer diagnosis and radiation therapy were analyzed for their association with overall survival in eight patients.RESULTS: KPS of 80-90% was significantly associated with better overall survival (p=0.006), one or no other metastatic sites showed a trend for a better outcome (p=0.10). The following scores were assigned: KPS 60-70%=0 points, KPS 80-90%=1 point, ≥2 other metastatic sites=0 points, 0-1 other metastatic sites=1 point. Two groups, with 0 and with 1-2 points, were formed. Overall survival rates were 33% vs. 100% at 6 months and 0% vs. 100% at 12 months (p=0.006), respectively.CONCLUSION: A simple instrument enabling physicians to judge the overall survival of patients with intracerebral metastasis from testicular cancer is provided.

KW - Adult

KW - Aged

KW - Brain

KW - Brain Neoplasms

KW - Humans

KW - Kaplan-Meier Estimate

KW - Karnofsky Performance Status

KW - Male

KW - Middle Aged

KW - Neoplasm Metastasis

KW - Prognosis

KW - Survival Rate

KW - Testicular Neoplasms

KW - Journal Article

U2 - 10.21873/anticanres.11042

DO - 10.21873/anticanres.11042

M3 - SCORING: Journal article

C2 - 27630334

VL - 36

SP - 4817

EP - 4819

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 9

ER -